602 European multi-disciplinary tumour boards support cross-border networking and increase treatment options for patients with rare tumours

Introduction/Background* EURACAN is the European reference network for rare adult solid tumours coordinated by the French Comprehensive Cancer Centre Leon Berard in Lyon, France. It consists of 10 domains, of which rare gynaecological tumours make up domain 2 (G2). Within the G2 domain, virtual multidisciplinary tumour boards (MDTs) were created to get support in clinical management of rare tumours. The aim of this report is to evaluate the outcomes in terms of participation, adherence to recommendations and access to novel patient treatment strategies. Methodology EURACAN G2 cross-border MDTs were initiated in November 2017 and organized by Karolinska University Hospital, Stockholm, Sweden. The MDTs were held monthly at pre-set dates and G2 health care providers (HCP) were invited to present patient cases. A standardized form was used for patient data collection and summaries of cases to be discussed was distributed to all HCPs before each MDT. A video- and telephone conference system was used for the first two years, and thereafter Webex meetings. After each MDT, a meeting summary with treatment recommendations was sent to all HCPs and the project manager at the coordinating centre. MDT format and outcomes were discussed at G2 domain meetings. Data regarding clinical characteristics of discussed cases and treatment recommendations were registered in a prospective database. Follow up data were retrieved until May 15, 2021. Result(s)* Between November 2017 and December 2020, 31 MDTs were held with participants from 10 countries and 20 HCPs. 91 individual patients were discussed between one and six times for a total of 109 case discussions. Background data is presented in table 1. Follow-up data was retrieved from 64 patients and 80 case discussions (table 2). Adherence to treatment recommendations was 99%. As a result of MDT recommendations, 11 patients got access to off-label treatment and one patient was enrolled in a clinical trial in another European country. 14/91 patients were recommended surveillance only. Conclusion* Cross-border MDTs enable networking and clinical collaboration between health care professionals in different countries. Surveillance strategies, off-label drug use and participation in clinical trials in other countries are possible benefits to patients with rare gynecological tumours.